PACTR202105463874444尚未招募4 期
ACTION III: A multi-country, multi-centre, three-arm, parallel group, double-blind, placebo-controlled, randomized trial of two doses of antenatal corticosteroids for women with a high probability of birth in the late preterm period in hospitals in low-resource countries to improve newborn outcomes
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 2,520
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- Female
入选标准
- •Gestational age from 34 weeks 0 days to 36 weeks 5 days
- •High probability of late preterm birth (up to 36+6 weeks) defined as birth expected between 12 hours and 7 days after randomization as a result of:
- •A. Membrane rupture without preterm labour (where preterm labour is defined as at least 6 regular uterine contractions/ hr and any one of the following: cervical dilatation of = 3 cm or effacement =75%). OR
- •B. Preterm labour with intact membranes, defined as at least 6 regular contractions/hr and one of the following: (i) cervix =3cm dilated or (ii) 75% effaced; OR
- •C . Planned delivery by induction of labour or caesarean section between 24hours and 7 days, as deemed necessary by the provider. An induction must be scheduled to start by 36+5 weeks at the latest, whereas a caesarean delivery must be scheduled by 36+6 weeks at the latest
- •Singleton or multiple pregnancies, where the foetus/es (or at least one foetus in a multiple pregnancy) is/are confirmed alive by doppler or USG
- •Women with no clinical signs of severe infection (as per obstetric care physician’s assessment)
- •Women willing and able to provide consent (or if a minor, provides assent and guardian provides consent)
- •Women with the following conditions will be eligible. Any comorbid conditions will be managed according to local guidelines, and in line with WHO recommendations:
- •oWomen with a history of previous preterm birth
- •oWomen with hypertensive disorders
- •oWomen with a growth impaired foetus
- •oWomen with pre-gestational or gestational diabetes
- •oWomen with HIV/AIDs
排除标准
- •Ruptured membranes with cervix dilated = 3cm or effaced =75%, or with more than 6 contractions per hour (or both)
- •Cervical dilation = 8 cm with intact membranes
- •Clinical suspicion or evidence of clinical chorioamnionitis or severe infection, as per obstetric care physician assessment
- •Evidence of non-reassuring foetal status requiring immediate delivery
- •Major or lethal congenital foetal anomaly identified
- •No prior ultrasound-based estimate of gestational age available and immediate ultrasound examination is not possible
- •Any systemic corticosteroid use during the current pregnancy (outside of trial)
- •Unwilling or unable to provide consent or assent (including due to active labour)
- •Currently a participant in another clinical trial related to maternal and neonatal health, or previously participated in any ACTION trial
- •Any other clinical indication where the treating clinician considers corticosteroids to be contraindicated
研究者
相似试验
招募中
3 期
Improving newborn survival in preterm birthCTRI/2021/03/032429World Health Organization
进行中（未招募）
不适用
A clinical study of the FAI Insert in patients with uveitis in the back of the eye that is not caused by an infectiochronic non-infectious uveitis affecting the posterior segment of the eyeMedDRA version: 16.0Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disordersEUCTR2013-001810-14-ITpSivida Corporation120
进行中（未招募）
1 期
A clinical study of the FAI Insert in patients with uveitis in the back of the eye that is not caused by an infectiochronic non-infectious uveitis affecting the posterior segment of the eyeMedDRA version: 18.0Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disordersEUCTR2013-001810-14-HUpSivida Corporation120
进行中（未招募）
1 期
A clinical study of the FAI Insert in patients with uveitis in the back of the eye that is not caused by an infectiochronic non-infectious uveitis affecting the posterior segment of the eyeMedDRA version: 19.0 Level: PT Classification code 10046851 Term: Uveitis System Organ Class: 10015919 - Eye disordersEUCTR2013-001810-14-GBpSivida Corporation129
进行中（未招募）
Unknown
A trial of different nutritional supplements and subsequent support to secure and sustain the recovery of moderately undernourished young children recovering from an illnessModerate wasting in children 6-24 months of ageNutritional, Metabolic, EndocrineISRCTN53213318World Health Organisation6,360